Cargando…

Evaluation of the HbA1c Reduction Cut Point for a Nonglycemic Effect on Cardiovascular Benefit of Hypoglycemic Agents in Patients with Type 2 Diabetes Based on Endpoint Events

BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is a major cause of death among patients with diabetes but can be improved by certain hypoglycemic agents. However, adjudicating criteria on whether improvements are a glycemic or nonglycemic effect of these agents remain unclear. METHODS: H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Yuchao, Tang, Lizhi, Zhang, Fang, Yan, Zhe, Li, Jing, Tong, Nanwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933032/ https://www.ncbi.nlm.nih.gov/pubmed/29849624 http://dx.doi.org/10.1155/2018/8457538

Ejemplares similares

Nonglycemic Outcomes of Antidiabetic Medications
por: Morse, Christopher, et al.
Publicado: (2019)

Trends in HbA(1c) thresholds for initiation of hypoglycemic agents: Impact of changed recommendations for older and frail patients
por: Ambrož, Martina, et al.
Publicado: (2020)

Effective Utilization of Oral Hypoglycemic Agents to Achieve Individualized HbA1c Targets in Patients with Type 2 Diabetes Mellitus
por: Bannister, Margaret, et al.
Publicado: (2016)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Definition of Norma / Prediabetes Cut-off Point for Fasting Glycaemia on the Basis of Glucose Tolerance Test and HbA1c Interrelationships
por: Ismayilova, Sevil, et al.
Publicado: (2021)

Measurement of HbA(1c) and HbA(2) by Capillarys 2 Flex Piercing HbA(1c) programme for simultaneous management of diabetes and screening for thalassemia
por: Ke, Peifeng, et al.
Publicado: (2017)

An Evaluation of Point-of-Care HbA1c, HbA1c Home Kits, and Glucose Management Indicator: Potential Solutions for Telehealth Glycemic Assessments
por: Zaharieva, Dessi P., et al.
Publicado: (2022)

Standardization of the HbA(2) Assay
por: Paleari, Renata, et al.
Publicado: (2018)

Cutoff Point of HbA1c for Diagnosis of Diabetes Mellitus in Chinese Individuals
por: Wang, Bing, et al.
Publicado: (2016)

Trends in Quantification of HbA1c Using Electrochemical and Point-of-Care Analyzers
por: Mandali, Pavan Kumar, et al.
Publicado: (2023)

GLP-1 Receptor Agonists: Nonglycemic Clinical Effects in Weight Loss and Beyond
por: Ryan, Donna, et al.
Publicado: (2015)

Glycemic and nonglycemic mechanisms of congenital malformations in hyperglycemic pregnancies: a narrative review
por: Negrato, Carlos Antonio, et al.
Publicado: (2022)

HbA(1c): The lower the better?
por: Araki, Eiichi, et al.
Publicado: (2011)

The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables
por: Lind, Marcus, et al.
Publicado: (2009)

Haemoglobin J-Baltimore can be detected by HbA(1c) electropherogram but with underestimated HbA(1c) value
por: Brunel, Valéry, et al.
Publicado: (2016)

Point-of-Care Measurements of HbA(1c): Simplicity Does Not Mean Laxity With Controls
por: Leca, Viviane, et al.
Publicado: (2012)

Variation in Point-of-Care Testing of HbA1c in Diabetes Care in General Practice
por: Kristensen, Troels, et al.
Publicado: (2017)

Comparison of a point-of-care analyser for the determination of HbA1c with HPLC method
por: Grant, D.A., et al.
Publicado: (2017)

Assessing the Clinical Utility of Point of Care HbA1c in the Ophthalmology Outpatient Setting
por: Mamtora, Sunil, et al.
Publicado: (2021)

Change in HbA(1c) over 3 years does not improve the prediction of cardiovascular disease over and above HbA(1c) measured at a single time point
por: Chamnan, P., et al.
Publicado: (2013)

Which Is the Most Appropriate Cut-Off of HbA1c for Prediabetes Screening in Caucasian Youths with Overweight or Obesity?
por: Di Bonito, Procolo, et al.
Publicado: (2023)

Influence of Serum Albumin on HbA1c and HbA1c-Defined Glycemic Status: A Retrospective Study
por: Feng, Xiaojing, et al.
Publicado: (2021)

Change in HbA(1c) Across the Baseline HbA(1c) Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
por: Gentilella, Raffaella, et al.
Publicado: (2019)

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
por: Ali, Amar, et al.
Publicado: (2019)

Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
por: Danne, Thomas, et al.
Publicado: (2019)

Hb H Interference on Measurement Of HbA1c With Ion-Exchange HPLC
por: Agilli, Mehmet, et al.
Publicado: (2013)

Drugs affecting HbA1c levels
por: Unnikrishnan, Ranjit, et al.
Publicado: (2012)

Current Status of HbA1c Biosensors
por: Lin, Hua, et al.
Publicado: (2017)

Labile glycated haemoglobin and carbamylated haemoglobin are still critical points for HbA(1c) measurement
por: Desmons, Aurore, et al.
Publicado: (2017)

Optimal glucose, HbA1c, glucose-HbA1c ratio and stress-hyperglycaemia ratio cut-off values for predicting 1-year mortality in diabetic and non-diabetic acute myocardial infarction patients
por: Sia, Ching-Hui, et al.
Publicado: (2021)

Hemoglobin variants detected by hemoglobin A1c (HbA1c) analysis and the effects on HbA1c measurements
por: Nasir, Nadzimah Mohd, et al.
Publicado: (2010)

In-House Algorithm for Reporting Discrepant HbA1c Result and Troubleshooting a Case of False Low HbA1c
por: Pant, Vivek, et al.
Publicado: (2021)

Estimation of mean erythrocyte age using HbA1c or HbA1c/glycated albumin for evaluation of anemia severity
por: Koga, Masafumi, et al.
Publicado: (2023)

The Best Cut-Off Value for HbA1c as a Screening Tool in Iranian Women With Gestational Diabetes Mellitus
por: Mousavi, Seyedeh Neda, et al.
Publicado: (2017)

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
por: Ouchi, Motoshi, et al.
Publicado: (2018)

Periodontal therapy as an adjunctive modality for HbA1c reduction in type-2 diabetic patients
por: Sundar, Chalini, et al.
Publicado: (2018)

RS12574989 and haplotype associated with α/β-chain imbalance and population HbA2 reduction
por: Lin, Qiyin, et al.
Publicado: (2022)

Multiple Nonglycemic Genomic Loci Are Newly Associated With Blood Level of Glycated Hemoglobin in East Asians
por: Chen, Peng, et al.
Publicado: (2014)

Impact of Sodium‐Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes
por: Trujillo, Jennifer M., et al.
Publicado: (2017)

Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
por: Ali, Amar, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9crs3t8b2fcvqo8inle4becs5c